Showcases Stock ranks Forex

Atara Biotherap (ATRA)
3.63  0.19 (5.52%) 08-08 16:00
Open: 3.58 Pre. Close: 3.44
High: 3.73 Low: 3.52
Volume: 1,725,297 Market Cap: 339M
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 3.732 - 3.743 3.743 - 3.756
Low: 3.488 - 3.501 3.501 - 3.515
Close: 3.607 - 3.627 3.627 - 3.649
Stock Technical Analysis
Target: Six months: 8.00
One year: 10.91
Support: Support1: 2.83
Support2: 2.35
Resistance: Resistance1: 6.85
Resistance2: 9.34
Pivot: 3.29
Moving Averages: MA(5): 3.32
MA(20): 3.68
MA(100): 6.33
MA(250): 11.70
MACD: MACD(12,26): -0.74
Signal(12,26,9): -0.83
%K %D: %K(14,3): 56.42
%D(3): 41.36
RSI: RSI(14): 41.20
52-Week: High: 20.04
Low: 2.83
Change(%): -70.7
Average Vol(K): 3-Month: 2059
10-Days: 2218
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ ATRA ] has closed below upper band by 17.1%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Mon, 08 Aug 2022
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update - Business Wire

Fri, 05 Aug 2022
Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm - GlobeNewswire

Thu, 04 Aug 2022
2022-08-04 | NDAQ:ATRA | Press Release | Atara Biotherapeutics Inc. - Stockhouse

Wed, 03 Aug 2022
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference - The Bakersfield Californian

Wed, 03 Aug 2022
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of "Hold" from Analysts - MarketBeat

Tue, 26 Jul 2022
SG Americas Securities LLC Sells 11980 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 93.41
% Held by Insiders 70270000.00
% Held by Institutions 0.72
Shares Short (K) 11270
Shares Short Prior Month (K)
Stock Financials
EPS -341649984.000
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm) 454.0
Return on Equity (ttm) -47.3
Qtrly Rev. Growth 24100000.0
Gross Profit (p.s.) 98.056
Sales Per Share -103.954
EBITDA (p.s.) 18833332.000
Qtrly Earnings Growth -3.64
Operating Cash Flow (M)
Levered Free Cash Flow (M) -239.35
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales -0.04
Price to Cash Flow 1.63
Stock Dividends
Dividend Yield
Dividend Growth 8040000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android